Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose‐range study
@article{Guy1983PsychotropicAO, title={Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose‐range study}, author={W. Guy and G. Manov and W. Wilson and T. A. Ban and O. K. Fjetland and P. J. Manberg and A. T. Dren}, journal={Drug Development Research}, year={1983}, volume={3} }
In a 28‐day, dose‐range study, 11 chronic schizophrenic inpatients newly admitted to the hospital with acute exacerbations were administered a new antipsychotic, BW 234U, in daily doses ranging from 100 to 400 mg/day on a fixed/flexible schedule to determine therapeutic dose range, safety, and psychotropic activity with special regard to possible antiaggressive action. The results of weekly assessments with standard psychiatric rating instruments indicate that BW 234U has dual psychotropic… CONTINUE READING
Topics from this paper
15 Citations
BW234: A nondopamine receptor‐blocking antipsychotic drug without extrapyramidal side effects?
- Medicine
- 1985
- 13
Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics
- Psychology
- 1985
- 16
Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia
- Medicine
- Schizophrenia Research
- 1991
- 251
Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity.
- Psychology, Medicine
- Pharmacological reports : PR
- 2006
- 19
- PDF
BMY-14802 reversed the σ receptor agonist-induced neck dystonia in rats
- Chemistry
- Journal of Neural Transmission
- 2005
- 5
Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity.
- Chemistry, Medicine
- European journal of pharmacology
- 1996
- 23
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
- Medicine
- Expert opinion on therapeutic targets
- 2011
- 151
- PDF
References
SHOWING 1-4 OF 4 REFERENCES
Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
- Psychology, Medicine
- Biological psychiatry
- 1979
- 53
BW234U,(cis‐9‐[3–(3,5‐dimethyl‐1‐piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent
- Medicine, Chemistry
- The Journal of pharmacy and pharmacology
- 1982
- 53
ECDEU Assessment Manual for Psychopharmacology
- 1976